40 results about "DEAE Sephadex" patented technology

The invention discloses a method for extracting and purifying calf serum protein-removing extract, which comprises extracting calf venous blood, separating plasma, removing protein with ethanol, removing ethanol through decompression, charging composite proteolytic enzyme, subjecting supernatant fluid to ultrafiltration, desalinizing ultrafiltrate with gluglucosan G-15 gel chromatography, collecting elution portion with specific absorption at 280nm, then separating with DEAE-Sephadex-50 gel chromatography, collecting elution portion with specific absorption at a second 280nm, then carrying out virus deactivation by means of microporous membrane filtration and ultraviolet irradiation.

The invention relates to a spirulina phatensis polysaccharide and an extraction method thereof. The extraction method comprises the following steps: after multigelation and wall breaking of a spirulina phatensis powder suspension, centrifuging to obtain a cell lysate 1 and cell debris; adding ammonium sulfate in the cell lysate 1 until the saturation is 50%, after salting-out precipitation, centrifuging to remove phycobiliprotein to obtain a supernatant, and evenly mixing the supernatant and the cell debris to obtain a cell lysate 2; obtaining a spirulina phatensis polysaccharide crude extract by using a hot water extraction method; adding the crude extract to an ethanol/ammonium sulfate aqueous two-phase system, and extracting to obtain a bottom-phase solution of spirulina phatensis polysaccharide with higher purity; after the bottom-phase solution is desalted by dialysis, eluting by using a Sephadex G-150 chromatographic column and a DEAE Sephadex A-50 anion exchange column to obtain a pure spirulina phatensis polysaccharide solution; and freeze-drying, thereby obtaining a pure spirulina phatensis polysaccharide finished product. The extraction method can be used for avoiding the traditional complicated protein removal operation steps, has low cost, high yield, and high purity and activity of polysaccharide, and is suitable for intermittent and large-scale production and processing.

A process for preparing monosialic acid tetra-hexose ganglioside preparation from pig's brain includes such steps as ultrafilter membrane separation, chromatography by Iatrobeads column and DEAE sephadex A-25 column, and efficient liquid-phase chromatography technique. In the preparation process, it retains the GMI amphipathy physico-chemical characteristic of ganglioside. Its advantages are highpurity (more than 95%), low cost, environment protection and high curative effect.

The invention relates to an acidic oligosaccharide having weight-reducing and lipid-lowering effects and application thereof. The adopted technical scheme is that a preparation method of the acidic oligosaccharide is as follows: taking pectin water solution with the weight percentage concentration of 1 percent to 2 percent, regulating pH to 2 to 4, decomposing and reacting the solution for 15 minutes to 24 hours at 90 to 120 DEG C to obtain pectin decomposer, treating the pectin decomposer by a hollow fiber membrane or a ceramic filter membrane, recovering oligosaccharide mixtures with the molecular weight of lower than 6000 daltons, recovering the oligosaccharide mixtures with the molecular weight of 200 to 6000 daltons through a nano-filter membrane, carrying out chromatographic separation by utilizing Bio-gel P-2 gel column or SephadexG-25 gel column or DEAE-Sephadex A-25 anion exchange resin, and carrying out gradient elution by utilizing inorganic salt water solution to obtain the pectin acidic oligosaccharide with the contact ratio of 2 to 20. The acidic oligosaccharide prepared by the invention can be applied to weight-reducing and lipid-lowering health food.

The invention discloses a method for simultaneously preparing high-purity human coagulation factor VIII and human fibrinogen by cryoprecipitate and component I precipitation, mixing and feeding. The method comprises the following steps: (1) simultaneous feeding and dissolution of a cryoprecipitate and a component I; (2) DEAE Sephadex A-50 gel adsorption; (3) S/D virus inactivation; (4) anion exchange column chromatography; (5) two-step low-temperature ethanol precipitation and purification, sterile filtration, subpackage, freeze-drying and dry heat virus inactivation of a chromatographic penetration liquid to obtain a human fibrinogen; (6) further hydrophobic column chromatography of a chromatographic eluant; (7) ultrafiltration, nanofilm filtration, sterile filtration, subpackage, freeze-drying and dry heat virus inactivation of a hydrophobic eluant to obtain a high-purity human coagulation factor VIII. By the adoption of the process, FVIII and Fg in the two raw materials are extracted simultaneously, so that the yields of the two products are greatly improved, the yield of the human coagulation factor VIII can reach 200,000 IU/ton plasmas, the yield of the human fibrinogen exceeds 2,000 bottles/ton plasmas, and the yields are both far higher than those of a traditional process.

The invention relates to a production method of human antithrombin III. The production method comprises the following steps: removing cryoprecipitate from fresh frozen human plasma to obtain a plasma supernatant, and carrying out adsorption treatment on the plasma supernatant by using a DEAE Sephadex-A50 gel; precipitating impurity protein of the plasma supernatant, and deeply filtering plasma; carrying out Capto Heparin affinity chromatography; carrying out S/D virus inactivation and Capto Q ion exchange chromatography, and removing an S/D reagent; and filtering by virtue of a nanometer film to remove viruses, preparing, freeze-drying and dry-heating. The process is capable of preparing the antithrombin III by virtue of affinity chromatography with only one step. According to the production method disclosed by the invention, the recovery rate can reach above 40 percent, and the specific activity can reach 8-10 IU/mg.

This invention relates to a method for preparing antivirus active oligomerized peptides by step directional enzymolyzing oysters with a compound enzyme characterizing in adding Tris-HCL buffer solution into the oyster meat to be beated, the increased number of the buffer is 2-3 times of kilograms of the meat, trypsase is added according to the proportion of 60-65U/g meat to be mixed under constant temperature and enzymolyzed for 3-4 hours under 40-50deg.C then to eliminate the enzymes and cool, regulating pH value to 5-6 with an acid and adding pineappleproteinase in the meat proportion of 70-75U/g to be mixed and enzymolyzed for 5-6 hours under the 45-55deg.C constant temperature to eliminate the enzymes and cool, centrifuge to take the supernatant fluid to pass through super-filtration, Sephadex G-25 gel chromaphoresis, DEAE Sephadex A-25 ionic exchange post chromaphoresis and counter-phase high efficient liquid phase chromqtogram separation and purification to be frozen and dried.

The invention discloses water-soluble low-molecular-weight polysaccharide with anti-tumor activity for artificially cultured cordyceps mycelium, a preparation method and an application thereof. 30 percent ethanol is used as extractant, and the best extraction process of the polysaccharide has the temperature of 70 DEG C, material-liquid ratio of 1 to 20, and extracting time of 2 hours. The polysaccharide is subjected to grease removal, protein removal, 50 percent ethanol precipitation and 70 percent ethanol precipitation to prepare crude polysaccharide after freezing and drying. The crude polysaccharide is purified grade by grade through a DEAE Sephadex A-25 column and a Sephadex G-75 column to prepare the water-soluble low-molecular-weight polysaccharide. The polysaccharide has higher purity, wherein the polysaccharide content is 94.57 percent, and relative molecular mass is about 9,874. The water-soluble polysaccharide has obvious inhibiting effect on proliferation of liver cancer cell line Bel-7204 and gastric cancer cell line SGC-7901 of human beings, and has obvious inhibiting effect on growth of S180 tumor cells implanted in a mouse body. The water-soluble low-molecular-weight cordyceps polysaccharide has clear active components and controllable quality, and can be used as an anti-tumor medicament or a health-care product for improving body immunity.

The invention belongs to the technical field of biotechnology and provides a purification method of deproteinized calf blood serum extract. The purification method includes collecting calf venous blood, separating to obtain serum, deproteinizing with ethanol, decompressing to remove the ethanol, adding compound protease for hydrolization, centrifugally separating after hydrolization and reserving supernatant, and ultra-filtrating the supernatant; subjecting ultrafiltrate to gel chromatography with Sephadex G-15 for desalting, and collecting specific absorption elution at 280nm position; performing gel chromatographic separation with DEAE-Sephadex-50, and collecting specific absorption elution at the second 280nm position; and filtering with microporous membranes and inactivating viruses by ultraviolet irradiation so as to obtain the deproteinized calf blood serum extract. A great many of inactive ingredients are removed, molecular weight range of products is reduced, probability of adverse reactions is reduced, product purity, safety and bioactivity are improved, and the purification method is widely applicable.

The invention discloses a fritillariae cirrhosae bulbus polysaccharide extraction, separation and purification technology. As a novel supercritical CO2 extraction technology is utilized, the defects that a general method is low in extraction rate and not high in purity are overcome; quaternary ammonium salt cetyl pyridinium chloride monohydrate and fritillariae cirrhosae bulbus polysaccharide can precipitate in water solution with low ionic strength; when the ionic strength is high, precipitate can be dissolved, dissociated and released, and the purification effect is good; DEAE-Sephadex ionic exchange column chromatography is utilized to further remove neutral impurities and impurities with positive charges, and the separation and purification effect is better.

The invention discloses a preparation method of plasma human immunoglobulin. The preparation method includes the steps: (1) performing plasma removal and cryoprecipitation; (2) adsorbing impurities inplasma adsorbed by DEAE (diethyl-aminoethanol) Sephadex A50 gel, and performing Heparin affinity chromatography to enter next treatment, and directly treating the plasma not subjected to the DEAE Sephadex A50 gel in a next step; (3) performing FI+FII+FIII precipitation, impurity adsorption and redissolving; (4) performing FII precipitation, impurity adsorption and redissolving; (5) performing impurity adsorption and chromatography on redissolved FII supernatant; (6) performing ultrafiltration concentration and sterilization preparation; (7) performing low-pH (potential of hydrogen) incubation. The purity of an immunoglobulin product produced by the preparation method is higher than or equal to 99%, no blood coagulation factors are detected, detection is performed by NaPTT and a developingsubstrate method, and FXI and FXIa contents of the final IgG product are below detection limit.

The invention provides a process for purifying a prothrombin compound. The process comprises the following steps: subjecting qualified detected plasma of a healthy person to centrifugation for removal of sediments so as to a raw plasma material; subjecting the raw plasma material to adsorption with DEAE-Sephadex A-50 gel and carrying out washing and elution so as to obtain crude extract of the prothrombin compound; and subjecting the crude extract of the prothrombin compound to further adsorption by using Capto DEAE gel column chromatography and carrying out washing and elution so as to obtain the liquid prothrombin compound. According to the invention, the prothrombin compound is prepared through two-step operations via the DEAE-Sephadex A-50 gel and Capto DEAE gel; and under the designed process conditions, the prepared prothrombin compound has a purity far higher than the purity of a prothrombin compound product prepared by using a traditional process, and blood coagulation factors II, IX and X are good in equalization.

The invention discloses a preparing method of high-purity lobulantina, which is characterized by the following: adopting chromatography medium of DEAE-Sephadex A-50 as ionic exchange chromatography column, using PH as 6.5-8.5 and density is 0.005-0.07mol/L sodium acetate buffer solution to dissolve PMSG semifinished product and up-sample, using PH is 6.5-8.5 and density is 0.005-0.07mol/L sodium acetate buffer solution to break so as to remove foreign matter, using PH is 6.5-8.5 and density is 0.15-0.3mol/L sodium acetate buffer solution to elute and check at the some time, assembling eluent to get collecting solution, dialyzing and freeze-drying collecting solution to get elaboration product.

The invention discloses a preparation method for human antithrombin III (AT-III). The preparation method comprises the following steps: (1) precipitation and dissolution of a blood plasma fraction IV; (2) polyethylene glycol (PEG) precipitation and impure protein removing; (3) DEAE Sephadex A-50 gel adsorption; (4) S/D virus inactivation; (5) heparin affinity column chromatography; (6) ultrafiltration and concentration; (7) addition of a stabilizer and regulation; (8) nanofilm virus-removing filtration; (9) sterilizing filtration; (10) freeze-drying; (11) dry and fever virus inactivation. According to the preparation method, blood coagulation factors, which remain in the raw materials and are depended by vitamin K, are removed, so as to greatly lower the possibility of protein activation in the production process, and improve the product qualification ratio; PEG is adopted for the impure protein removing, so as to reduce the load of a chromatographic column; a liquid obtained from lyophilized powder re-dissolution is clear, transparent, and free of protein precipitation and opalescence; through adoption of a three-step virus inactivation method, the safety of human AT-III for clinical use can be greatly improved.

The invention discloses an extraction method of polysaccharide with activities of kidney warming and Yang tonifying from Aspongopus chinensis Dallas insects of Pentatomidae and application of the polysaccharide. The extraction method comprises the following steps: (1) drying Aspongopus chinensis Dallas insect bodies, performing pulverization, performing reflux extraction with petroleum ether, andconducting filtration liquid-solid separation so as to obtain drug residues with removal of grease; (2) evaporating the drug residues, performing reflux extraction with distilled water, performing filtration, combining the filtrate, and performing concentration so as to obtain total water extract; (3) adding distilled water to the total water extract for slight dilution, performing precipitation on polysaccharide with an alcohol solution, performing stirring while the alcohol solution is added, and performing still standing and filtration so as to obtain an insect polysaccharide alcohol precipitate; and (4) adding water to the insect polysaccharide alcohol precipitate for dilution and dissolution, performing chromatography separation and purification by using a DEAE-Sephadex ged cellulosecolumn, and performing rinsing with distilled water and a sodium chloride solution so as to obtain the Aspongopus chinensis Dallas polysaccharide. The invention also relates to the application of thepolysaccharide in preparation of drugs for treating or preventing Yang deficiency, impotence and erectile dysfunctions, the method is easy has simple and convenient operation, and the obtained polysaccharide compound with a purity of up to 95% has strong effects of kidney warming, Yang tonifying, fatigue resistance and body immunity recovery.

The invention relates to an application of pectic acid oligosaccharide in preparing a health-care product treating gastric ulcer. The invention adopts the technical scheme that firstly, pectin is dissolved in water, and a pectin decomposer is prepared by a decomposition reaction; the pectin decomposer is processed by using a hollow fibre film or a ceramic filtration film, an oligosaccharide mixture with the molecular weight of 200-6000 daltons is processed and recovered by using a nano filtration film after an oligosaccharide mixture with the molecular weight being below 6000 daltons is recovered, and the pectic acid oligosaccharide with the superposition degree of 2-20 is obtained by the chromatographic separation of a Bio-gel P-2 gel column and/or a Sephadex G-25 gel column or the filtration of DEAE-Sephadex A-25 anion exchange resin. The prepared pectic acid oligosaccharide and auxiliary materials are matched to prepare health-care products with various forms and components for treating the gastric ulcer. The invention adopts a congeneric theory of medicines and foods, has no toxic or side effect and can be taken for a long time. By verification, the invention has obvious curative effect to sour burning type gastric ulcer.

Helicobacter pylori is closely associated with chronic gastritis, peptic ulcer disease, and gastric adenocarcinoma. Helicobacter pylori neutrophil-activating protein (HP-NAP), a virulence factor of Helicobacter pylori, plays an important role in pathogenesis of Helicobacter pylori infection. Since HP-NAP has been proposed as a candidate vaccine against Helicobacter pylori infection, an efficient way to obtain pure HP-NAP needs to be developed. In the present invention, recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli was purified through a single step of DEAE Sephadex ion-exchange chromatography with high purity. Also, purified recombinant HP-NAP was able to stimulate neutrophils to produce reactive oxygen species. Thus, recombinant HP-NAP obtained from our Bacillus subtilis expression system and Escherichia coli expression system is functionally active. Furthermore, this one-step negative purification method should provide an efficient way to purify recombinant HP-NAP expressed in Bacillus subtilis and Escherichia coli for basic studies, vaccine development, or drug design.

The invention relates to a technique of an enzyme. The technique of the enzyme comprises the following steps: (1) carrying out a DEAE-sephadex A50 balance method; and (2) carrying out a linear elution method, wherein nine peaks are separated in total, and qualified peaks are combined. The technique provided by the invention has the advantages that a technique for extracting defibrase by virtue of snake venom is adopted, and compared with the original technology, separation time is short, usage amount of a reagent is small, process is simple, yield is high, and quality is stable.

The invention discloses a technology for extracting hyaluronic acid from squid eyes. The technology comprises the following steps: 1) cleaning the fresh squid eyes and smashing; 2) subcritical water extraction: putting a processed raw material into an extraction kettle, adding sodium acetate, injecting deoxidized deionized water into the kettle, controlling an extraction temperature as 120 to 130DEG C, pressure as 5 to 8 MPa and extraction time as 20 to 30 minutes, extracting the squid eyes, releasing pressure after extraction finishes, making extract liquor flow into a collection tank to becooled to room temperature to obtain the extract liquor; 3) adding an isometric chloroform and n-butyl alcohol mixed solution into the extract liquor obtained in the last step, evenly stirring and standing, wherein a volume ratio of the chloroform to the n-butyl alcohol is equal to 4 to 1; 4) purification: taking supernatant after standing and layering to pass through a DEAE-SephadexA-25 ion column and eluting by a NaCl solution to obtain eluant; 5) drying: concentrating the eluant, dialyzing to remove salt and vacuum drying to obtain a finished product.

The invention discloses a process for extracting hyaluronic acid from cockscombs. The process comprises the following steps: (1) cleaning and crushing fresh cockscombs; (2) performing subcritical water extraction: putting the treated raw material into an extraction kettle, adding sodium acetate, injecting deoxygenated deionized water into the kettle, extracting the cockscombs at extraction temperature of 120 to 130 DEG C and pressure of 5 to 8 Mpa for 20 to 30 min, relieving the pressure at the end of the extraction, and putting extraction liquid into a collection tank for cooling to room temperature, thus obtaining extraction liquid; (3) performing suction filtration: adding kieselguhr which accounts for 0.010 to 0.012 of the weight of the extraction liquid into the extraction liquid obtained in the previous step, and performing suction filtration at 0.1 MPa, thus obtaining filtrate; (4) performing purification: putting the filtrate obtained in the previous step through a DEAE-Sephadex A-25 ion column, and eluting the filtrate with a NaCl solution, thus obtaining eluent; (5) performing drying: concentrating the eluent, dialyzing the eluent to remove salt, and performing vacuum drying to obtain a finished product.

The invention discloses a preparation method of mono-sulfonated Lewis trisaccharide. The preparation method of the mono-sulfonated Lewis trisaccharide comprises the following steps: (1) dissolving 300-350 mg of 8-p-methoxy-benzeneoctanoxy 2-acetamido 3-O-(b-D-galactopyranoside) 4-O-(2, 3, 4-tri-O-benzyl a-L-fucopyranoside) 2-deoxidation-b-D-glucopyranoside 0.3 mmol/L in 3-5 mL of anhydrous pyridine, then adding 85-100 mg of a sulfur trioxide pyridine complex 0.6 mmol/L, mixing and stirring for 14-15.5 hours at the temperature of 78-82 DEG C, adding methylbenzene, and evaporating a cosolvent to obtain original residues; (2) dissolving the original residues in 4-5 mL of a mixed solvent of methanol and acid, adding a palladium or carbon catalyst, stirring for 25-32 hours at the room temperature under the condition that hydrogen exists, and removing the catalyst and the mixed solvent to obtain residues; (3) placing the residues in DEAE-Sephadex A-50 columns, removing sulfated saccharide by elution with water, and eluting a mono-sulfonatedsaccharide component and a sulfated saccharide component by using a NaCl solution with the molar concentration of 5% and a NaCl solution with the molar concentration of 15% separately; and (4) loading residues obtained after a mono-sulfonated fraction is desolventized on C-18 columns, eluting the residues with water and then washing the residues with methanol to obtain the mono-sulfonated Lewis trisaccharide. The preparation method is the most effective method for generating sulfonic acid oligosaccharideuntil now.

The invention relates to a C1 esterase inhibitor and a preparation method thereof, and belongs to the field of biological pharmacy. The C1 esterase inhibitor is prepared from a washing solution which flows out of a chromatographic column in a DEAE Sephadex A50 gel adsorption process and is a waste material obtained by preparing a human prothrombin complex from plasma, and is purified by a PEG precipitation method and refined by capto MMC ion exchange chromatography, and the specific activity of a final finished product is higher than 6IU/mg.